OBJECTIVE: To report the effect of long-term treatment with the tyrosine kinase inhibitor imatinib started before the onset of puberty on semen parameters, bone mineral density, and hormone values. DESIGN: Case report. SETTING: University hospital. PATIENT(S): An 18-year-old man given treatment with imatinib for chronic myeloid leukemia. INTERVENTION(S): Clinical, biochemical and dual-energy X-ray absorptiometry evaluations. MAIN OUTCOME MEASURE(S): Semen analysis, serum levels of gonadotropins, inhibin-B, and testosterone, bone mineral density, markers of skeletal homeostasis. RESULT(S): Semen analyses showed severe oligozoospermia after long-term administration of imatinib started before puberty. The inhibin-B/FSH ratio was reduced. A low bone mineral density for chronologic age was observed. CONCLUSION(S): This case study documents the potential risk of an impairment of semen parameters in patients undergoing a treatment with tyrosine kinase inhibitors before the complete maturation of the testis.
OBJECTIVE: To report the effect of long-term treatment with the tyrosine kinase inhibitor imatinib started before the onset of puberty on semen parameters, bone mineral density, and hormone values. DESIGN: Case report. SETTING: University hospital. PATIENT(S): An 18-year-old man given treatment with imatinib for chronic myeloid leukemia. INTERVENTION(S): Clinical, biochemical and dual-energy X-ray absorptiometry evaluations. MAIN OUTCOME MEASURE(S): Semen analysis, serum levels of gonadotropins, inhibin-B, and testosterone, bone mineral density, markers of skeletal homeostasis. RESULT(S): Semen analyses showed severe oligozoospermia after long-term administration of imatinib started before puberty. The inhibin-B/FSH ratio was reduced. A low bone mineral density for chronologic age was observed. CONCLUSION(S): This case study documents the potential risk of an impairment of semen parameters in patients undergoing a treatment with tyrosine kinase inhibitors before the complete maturation of the testis.
Authors: Alberuni M Zamah; Michael J Mauro; Brian J Druker; Kutluk Oktay; Merrill J Egorin; Marcelle I Cedars; Mitchell P Rosen Journal: Oncologist Date: 2011-09-23